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A compelling body of non-randomized evidence has established stereotactic ablative lung
radiotherapy (SABR) as a standard of care for medically inoperable patients with peripheral
early-stage non-small cell lung cancer (NSCLC). This convenient outpatient therapy, which is
typically delivered in 3-8 fractions, is also well tolerated by elderly and frail patients, makes
efficient use of resources and is feasible using standard commercial equipment. The
introduction of lung SABR into large populations has led to an increased utilization of
radiotherapy, a reduction in the proportion of untreated patients and an increase in overall
survival. In selected patients, the same ablative technology can now achieve durable local
control of NSCLC metastases in a variety of common locations including the adrenal glands,
bone, brain, and liver. At the same time as this, advances in prognostic molecular markers
and targeted systemic therapies mean that there is now a subgroup of patients with stage IV
NSCLC and a median survival of around 2 years. This creates opportunities for new trials that
incorporate SABR and patient-specific systemic strategies. This selective mini-review
focuses on the emerging role of SABR in patients with early-stage and oligometastatic
NSCLC.
Key words
Non-small-cell lung carcinoma, Radiosurgery, Stereotactic body
radiotherapy, Clinical trial design
Max Dahele,MBChB, MSc, FRCP, FRCR
Suresh Senan,MBBS, PhD, MRCP, FRCR
Department of Radiation Oncology, 
VU University Medical Center, Amsterdam,
Netherlands
Correspondence: Suresh Senan, MBBS, PhD,
MRCP, FRCR
Department of Radiation Oncology, 
VU University Medical Center, De Boelelaan
1117, Postbox 7057, 1007 MB Amsterdam, 
Netherlands
Tel: 31-20-444-0436
Fax: 31-20-444-0410
E-mail: s.senan@vumc.nl 
Received  May 10, 2011
Accepted  May 19, 2011
DOI 10.4143/crt.2011.43.2.75
Review Article Open Access
Ԙhttp://www.cancerresearchandtreatment.orgԘ
Ԙhttp://www.e-crt.orgԘ
pISSN 1598-2998 eISSN 2005-9256
Stage I Non-small Cell Lung Cancer
Stereotactic ablative radiotherapy (SABR), which is also referred to
as stereotactic body radiotherapy (SBRT), is a form of high-precision
radiotherapy (RT). It is typically delivered in one to 8 intermittent
fractions, taking up to 2.5 weeks to complete and commonly using
fraction sizes of 7.5-20 Gy or more. This compares with 20 or more
fractions of 3 Gy or less taking up to 7 weeks to complete that is typical
of conventional RT (Fig. 1) [1,2]. Modern lung SABR is characterized
by patient-specific planning techniques that account for individual
tumor motion whilst delivering heterogeneous dose distributions to the
tumor and sparing normal tissues; accurate and reproducible image-
guided patient setup prior to and during each fraction; and ‘beam-on’
radiation delivery times that can be 10 minutes or less with some
techniques [3,4]. SABR can be delivered using standard commercial
equipment, and is readily incorporated into departmental workflows.
Local control rates of 90% or more are now possible with SABR for
peripheral stage I non-small cell lung cancer (NSCLC) measuring up
to 5 cm in maximum diameter [5,6]. The key to achieving this is be-
lieved to be a sufficiently high radiation dose delivered in only a few
fractions, combined with accurate tumour targeting [7,8]. These results
contrast impressively with those of conventional RT using doses of at
least 50-60 Gy in fraction sizes of 3 Gy or less, for which local failure
rates of 40-50% and more can be expected [9,10]. The combination of
improved local control and an acceptable toxicity profile mean that in
recent years, SABR has become the preferred treatment for patients
with medically inoperable stage I NSCLC in countries like the
Netherlands and Japan [11,12]. There are several important sources of
evidence to support this strategy. In addition to the institutional and
phase II studies already cited and a recent meta-analysis [13], there is
now encouraging population-based data [11]. In this latter study of pa-
tients aged 75-years or older, the introduction of SABR led to a 16%
absolute increase in utilization of RT, a decline in the proportion of
Copyright ˅2011 by  the Korean Cancer Association   75
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/     
licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution,  and reproduction in any medium, provided the original work is properly cited.Cancer Res Treat. 2011;43(2):75-82
76 CANCER  RESEARCH AND  TREATMENT
Fig. 1. This peripheral stage I lung tumor (left) was treated using 3 fractions of 18 Gy. The panel on the right side shows the colorwash
representing high-dose regions within the planning target volume (red contour).
Benchmark Comment
Is there equipoise amongst treating and referring  It is difficult to argue that there is equipoise or uncertainty given the local control data in favour of
physicians? SABR. This now includes institutional, phase II, meta-analysis and population-based sources
[5,6,11,13]. In a number of countries, SABR is now regarded as a standard of care for patients with
medically inoperable peripheral early-stage NSCLC.
Is one treatment as convenient as the other? This is not the case as SABR is typically delivered in 3-8 intermittent fractions and finished within  
1-2.5 wk [6], whereas conventionally fractionated RT may require upwards of 20-30 daily
fractions and take 4-6 wk or more to complete. More hypo-fractionated conventional treatments
require up to 15 daily fractions that can be delivered in 3 wk [18]. The available data suggests that
patient convenience and the efficacy and favourable toxicity associated with SABR may be key
factors that influence treatment uptake in elderly patients with co-morbidity [11]. Furthermore
recent advances in RT technology have enabled treatment times for each session of SABR to be
shortened considerably in recent times [4].
Do the two interventions represent equally  This is unlikely to be the case as modern conventionally delivered RT still requires image-guidance 
effective use of constrained resources? and it uses more treatment slots and a longer total time on the treatment machine (see above).
Combined with an a priori lack of equipoise, this means that conventional treatment might
actually use more resources for a less favourable outcome. Comparisons between the resources
required for an established conventional lung RT service with those deployed early on in a lung
SABR program (e.g., for treatment planning and quality assurance workflows) may be
inappropriate, as substantial improvements in overall efficiency can be expected with SABR once
experience increases and provided that the program is designed effectively. 
Are there lessons from other clinical scenarios? There are analogies to be drawn with localized prostate cancer, where no high-quality, RCT exists 
to support one active intervention over another [19]. There are other examples where a lack of
randomized data to support one intervention over another, including for example surgery versus
radiosurgery for brain metastases [20] has not hindered their widespread clinical use.
Are RCT the only way to assess lung SABR and  While some maintain that a RCT is the only way in which to truly evaluate an intervention, they
the associated technological advances? can have many potential limitations including cost, concerns over general applicability of
findings, insufficient power, the time taken to generate results and the risk that these will be
redundant when they are reported [21]. A RCT may also not be the best way in which to assess
technological advances [22], and it may be impractical or inappropriate when there is sufficient
alternative evidence to support a treatment, for example lung SABR for medically inoperable
early stage NSCLC, which is already standard of care in some countries.
Table 1. Reasons why a randomized clinical trial of conventional radiotherapy vs. SABR for medically inoperable peripheral stage I NSCLC
may be unlikely to succeed
SABR, stereotactic ablative radiotherapy; NSCLC, non-small cell lung cancer; RT, radiotherapy; RCT, randomized controlled trial.untreated elderly patients, and an improvement in overall survival. This
was statistically significant only for the subgroup treated using RT, in
which there was an estimated median increase in overall survival of 6
months, from 20 to 26 months, between cohorts of patients treated in
1999-2001 and 2005-2007. The survival benefits observed in this
population-based cancer registry are plausible as SABR has been
shown to be well tolerated in elderly patients [14], and in those with
severe chronic obstructive airways disease [15,16]. Both the baseline
and post-SABR cohorts are from the period after which fluorodeo-
xyglucose (FDG) positron emission tomography (PET) scanning
became widely available, increasing the likelihood that SABR may be
responsible for the improved outcomes. Although there have been
suggestions that higher quality evidence is needed to confirm the
improved therapeutic ratio for SABR over conventional RT before it
enters routine use [17] a randomized trial comparing these two
treatment approaches seems unlikely (Table 1) [18-22]. Indeed a
convincing argument could now be made against such a trial on the
grounds of a lack of uncertainty and clinical (community) equipoise
[23]. Where SABR is not available or accepted, it should be noted that
hypo-fractionated conventionally delivered RT is another option that
might also deliver improvements in local control. For example, 48-60
Gy in fractions of 4 Gy has been associated with actuarial local control
rates of 70% at 5 years [18]. 
In the protracted debate over supportive evidence, it is appropriate to
reflect on the seriousness of a diagnosis of lung cancer for today’s
patients, who require access to the best currently available treatment.
Analysis of the Surveillance, Epidemiology and End Results (SEER)
registry using data from elderly patients (ĥ65 years of age) diagnosed
with stage I or II NSCLC between 1992-2002 who were not treated by
surgery, found that if they also had no RT, their median survival was 7
months [24]. This could be increased by 6 months, to 13 months, when
they received RT, however only 59% of patients did so. Overall, 71%
of patients died of lung cancer progression. A recent Dutch analysis
showed that 38% patients of elderly patients presenting with stage I
NSCLC in the period between 1999-2001 received no local therapy
[11]. Many factors may influence the uptake of a treatment. For
example, protracted courses of conventional RT may be perceived as
ineffective, inconvenient and poorly tolerated by frail patients and their
clinicians. SABR addresses all of these concerns. Furthermore,
guidelines and training [3,25] combined with advances in technology
and quality assurance procedures may improve knowledge and
increase confidence, facilitating the adoption of new techniques. A
recent survey of SABR in the United States highlights other important
drivers including research (for academic radiation oncologists), and
competitive reasons (for those in private practice) [26]. However,
despite such levers, introducing technology into some healthcare
systems has been a major challenge. It is easy to overlook the fact that
the process needs to be actively managed with advance planning, clear
priorities and carefully considered implementation strategies [27]. 
One concern expressed by some has been the wide range of dose-
fractionation schemes reported in the lung SABR literature. However,
there is now appreciable clinical data from a variety of sources to
indicate that local control is compromised when a biological effective
dose (BED) of less than 100 Gy10 is delivered, calculated using an
alpha/beta ratio of 10 Gy [28-30]. Data from our own center reports
consistently high rates of initial tumor control across a range of ‘risk-
adapted’ dose-fractionation schemes, all with a BED105 Gy10 [6].
Caution is therefore required in advocating doses of less than 100 Gy10
for peripheral lung SABR of targets up to 5 cm in diameter, especially
when considering that such schedules are associated with low rates of
significant toxicity [31,32]. Indeed, high-grade toxicity and mortality is
uncommon following SABR for peripheral lung tumours, and rib
fractures and radiation pneumonitis have generally occurred in less
than 10% of patients (although the former may depend on such factors
as the proximity to the chest wall, dose-fractionation scheme and
planning/delivery technique) [31,32]. Damage to the brachial plexus
has been reported in patients treated for apical tumors, particularly
when plexus doses exceeded a BED of 100 Gy3 (i.e., calculated using
an alpha/beta ratio of 3 Gy) [33]. It remains to be seen if the incidence
of these complications will be reduced by the use of lower fraction
sizes for selected tumors located closer to critical structures. Such a
risk-adapted strategy was adopted when our lung SABR program
started in 2003, taking in to account factors such as tumor size/
treatment volume, the location of the target volume and the extent of
contact with the chest wall [6]. In some centers patients with tumors ĥ
5 cm and also those that are centrally located are now being treated
with risk-adapted SABR [34]. Follow up durations are currently
limited, and it should be noted that the safety profile of SABR for
central and to some extent larger tumors is likely to be different and so
neither the clinical toxicity data, nor many of the treatment schedules
for peripheral lung SABR should be directly extrapolated to these
scenarios. One example concerns central airway toxicity, which has
been reported after SABR for lung tumors extending into the me-
diastinum [35,36]. 
The role of non-surgical treatment options in patients who are
potentially fit to undergo surgery has increasingly been the subject of
discussion [37,38]. Recent reports of SABR have included small
numbers of patients who had declined to undergo surgery, and two
prospective single-arm trials of SABR in patients who are fit to
undergo surgery have completed accrual (JCOG 0403/NCT00238875
and RTOG 0618/NCT00551369). A Markov model analysis of
outcomes after either SABR or lobectomy for stage I NSCLC for a 5-
year time frame indicated that SABR might offer comparable overall
survival and quality-adjusted life expectancy as compared with surgical
resection [39]. This is consistent with a matched propensity analysis
from Washington University of 57 high-risk surgical patients and 57
patients undergoing SABR for stage I NSCLC, which found
comparable local control and disease specific survival between the two
groups at 3 years [40]. Importantly, both the 5- and 3-year time points
used in these studies are considerably longer than the median time to
loco-regional recurrence in patients who have had surgery for early-
stage NSCLC (see below) [41]. Current changes in demography mean
that more than half of new patients with lung cancer are older than 70
years, and the absolute number of elderly patient is projected to
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increase faster than the increase in the overall population [42]. Extra-
polating from a small sub-group analysis, SABR might be a parti-
cularly attractive treatment option for elderly patients as the benefits of
adjuvant chemotherapy for patients with occult nodal metastases
detected in stage I NSCLC resection were not apparent [43].
Furthermore, even in a study where the median patient age was 64
years, only 66% of patients who were candidates for adjuvant
chemotherapy post-surgery actually started chemotherapy [44]. 
Two issues that remain to be resolved in the coming years are
techniques for improving methods for the diagnosis of peripheral lung
tumours and for detecting local recurrence after SABR. Obtaining a
pre-treatment diagnosis in patients presenting with a peripheral lung
nodule suspicious for a lung cancer can be challenging, particular as
patients who are medically inoperable due to co-morbid disease, may
be at higher risk for complications following a trans-thoracic needle
biopsy. The likelihood of lung malignancy in this setting can be
calculated using a combination of clinical, radiological and PET
findings [45]. Applying this approach to SABR appears justified in a
country such as the Netherlands where a diagnosis of benign disease is
typically made in less than 5% of patients undergoing surgery [46-48].
However this policy may not be well suited to populations with a
higher likelihood of benign lung disease. Indeed, in some populations
the use of only a single computed tomography and PET scan without
other supportive data can lead to nearly one third of resected PET-
positive nodules turning out to be granulomas [49]. Improved diag-
nostic algorithms are clearly necessary in such populations. 
The pattern of disease failure after lung SABR is now well de-
scribed. Distant metastases predominate. In one study actuarial distant
failure-free survival rates of 85% and 77% were reported 1 and 2 years
post-SABR [6]. The rate of regional failure in patients staged with
FDG-PET is generally around 10% [31]. For patients who are fit
enough for potential salvage options, the early identification of local
recurrence is important. However post-SABR pulmonary changes may
be complex and can sometimes be hard to distinguish from tumor
progression [50]. This necessitates careful patient follow-up and access
to specialist multi-disciplinary teams who are familiar with interpreting
post treatment imaging. At the present time, one observation that may
help to discriminate local recurrence from post-SABR change is that
the former may be characterized by the rapid enlargement of a mass
within a relatively short period of time after lung SABR. This was the
case in recent reports describing experience with salvage surgery
[51,52] and is consistent with the timing of local-regional failure after
surgery. For example, a retrospective study of 975 patients undergoing
surgical resection for pathological stage I/II NSCLC between 1995-
2005 found that the median time from surgery to loco-regional failure
was 13.9 months [41]. Data such as these may help to guide optimal
follow up strategies, however they need to be complemented by
improvements in imaging and image analysis to discriminate between
recurrent tumor and post-SABR changes. The feasibility of surgical
salvage as a treatment option for recurrences post-SABR requires
further study, particularly as it may increase the preference for SABR
in some patients who are fit to undergo primary surgery.
Looking ahead, there are now a number of randomized clinical trials
comparing SABR and surgery but the results will not be available for
many years to come. The use of lung SABR for patients with
medically operable disease generates discussions about the relative
risks of the two interventions. In a recent population based analysis
from the Netherlands, lung SABR for medically inoperable patients
was associated with a 1% 30-day mortality when it was largely
delivered in only 2 regional centers [11]. This is similar in magnitude to
the post-operative 30-day mortality reported in the ACOSOG Z0030
study of pulmonary resection for early-stage lung cancer in medically
operable patients [53]. While results from individual centers can be
expected to vary, a population-based study using SEER data has linked
an increased risk of operative mortality to several factors, including
increased age and certain comorbidities [54]. This emphasizes the
importance of risk stratification and both expanding and
individualizing the therapeutic options for all patients with lung cancer.
The leading role played by the surgical community in studying the
impact of practice organization and operating protocols on patient
outcome is well recognized [55,56] and as lung SABR diffuses into
routine clinical practice throughout academic and community centers it
will also become important to learn from this experience and consider
similar issues in radiation oncology. 
Oligometastases from Non-small
Cell Lung Cancer
As survival in patients with stage IV NSCLC has historically been
considered to be poor, low-dose palliative RT has been the standard of
care in patients with symptomatic disease [57]. Justification for such an
approach was found for example in the outcome of a large phase III
trial comparing 4 different third-generation platinum-based
chemotherapy schemes [58]. This Eastern Cooperative Oncology
Group study reported a response rate for all 1,155 eligible patients of
19%, with a median survival of 7.9 months, a 1-year survival rate of
33% (95% confidence interval, 30 to 36%), and a 2-year survival rate of
11% (95% confidence interval, 8 to 12%). Such results indicated that
only a minority of patients would present with recurrent disease
requiring re-irradiation, and if needed repeat low-dose palliative RT
was the prevailing policy. A change in thinking regarding the
management of metastatic NSCLC lung cancer came about with
several publications, including those dating from the 1990’s when
long-term survival was noted selected patients who underwent
resection (or rarely RT) for limited volume metastatic disease, in
combination with radical management of the primary tumor [59,60]. 
Other studies have also suggested an advantage for ablative
management strategies in selected patients with advanced NSCLC. In
patients who present with newly diagnosed NSCLC and synchronous
brain metastases, a retrospective study in 167 patients from our own
institution has suggested that in a subgroup of selected patients aged 65
years or younger, who were also eligible to undergo surgery or radio-
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disease may be justified [61]. This strategy is indirectly supported by a
systematic review of randomized controlled trials of palliative thoracic
RT which concluded that improvements in survival were more likely
with higher-dose RT to the primary tumour (BED35 Gy10) [62]. Fur-
ther support is also provided by the observation that the predominant
pattern of failure in patients with advanced NSCLC after first-line
systemic therapy may be at the sites of known disease [63]. In keeping
with the view that cancer is a spectrum, it has been hypothesized that
the most relevant issue may not be whether or not there are distant
metastases, but instead what the ratio is between local and systemic
disease [64].  In this case, it is possible that the impact of chemotherapy
may be fairly similar for tumours that are either primarily localized or
systemic, whereas the benefit of adding chest RT could increase as the
proportion of tumour cells that are localized increases. 
Many institutional reports now show surprisingly long survival
outcomes in ‘definitively managed’ patients with metastatic NSCLC
[64], and recent guidelines, including those from the British Thoracic
Society, support the need for clinical trials of radical treatment for
patients with M1 disease [65]. At present, several non-invasive
treatment techniques, including SABR can be used to ablate meta-
stases. Reports evaluating SABR in the treatment of metastases to the
liver [66], adrenal gland (Fig. 2) [67], lung [68], brain [69], and bone
(Fig. 3) [70], have reported high rates of local control, sometimes in
excess of 90% when ablative doses of RT have been administered.
Lower radiation doses have been associated with lower rates of tumor
control. Together with recent developments in SABR, this has lead to a
resurgence of interest in the treatment of oligometastatic disease, a state
characterized by a limited number of clinically apparent metastases
with the possibility that these might genuinely represent the only
distant sites of disease [71,72]. Such treatment paradigms support a
move away from dichotomous definitions of treatments as curative or
palliative, encouraging a more useful spectral interpretation of
interventions and their potential for life-prolongation [32,63], as well as
debates about how best to integrate an increasing range of possible
therapies. 
Work is needed to identify who might benefit most from intensified
management strategies. One strategy, the identification of molecular
signatures that can augment clinical features, is a priority. In recent
Fig. 2. This patient had initially undergone resection of a T2N0 primary non-small cell lung cancer and single fraction stereotactic radiosurgery
for 2 synchronous brain metastases. Eleven mo later, after radiosurgery to 2 more brain metastases, they developed a solitary metastasis in the
right adrenal gland measuring 5.3 cm in diameter (left, arrow), which was treated with stereotactic ablative lung radiotherapy to a dose of 60 Gy
in 8 fractions. The 60 Gy dose (colored area, middle panel) tightly covers the treatment volume. A computed tomography scan 4 mo later shows a
reduction in diameter to 3.3 cm (right, arrow).
Fig. 3. This patient had previously undergone a single fraction of palliative radiotherapy for a painful vertebral metastasis, and subsequently
developed progressive local pain. A magnetic resonance imaging scan (left) revealed progressive vertebral destruction and thecal sac/spinal cord
compression. Whilst respecting the tolerance of the spinal cord,  stereotactic re-irradiation delivering a minimum dose of 8 Gy per fraction to most
of the tumor volume (colorwash) was possible. The patient received 2 fractions, and the maximum point dose in the tumor was 13 Gy per fraction.Cancer Res Treat. 2011;43(2):75-82
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randomized trials, treatment of NSCLC with activated mutations of the
epidermal growth factor receptor (EGFR) has shown response rates in
excess of 60%, and median survival exceeding 24 months [73,74]. The
identification of this and other molecular subtypes of stage IV disease
[75], where prolonged disease control can be attained using targeted
agents is now rapidly transforming the systemic treatment of stage IV
NSCLC. Studies evaluating the additional role of ablative therapies in
such patients with limited volume oligometastatic disease are a logical
step (Table 2), including in East Asian populations who have a higher
frequency of EGFR (and other) mutations [76]. Ultimately, one aim of
such treatment paradigms would be to achieve long-term survival,
although a less-controversial first step may be to prolong life while also
preserving quality and function [64]. A number of issues need to be
resolved before larger-scale trials can be initiated. Phase I-II data is
required to establish the toxicity of both sequential and concurrent
administration of molecularly targeted agents and high dose RT,
particularly as unexpected toxicities have been encountered [77]. In
addition, innovative and careful trial design is likely to be necessary to
increase the chance of successfully answering important clinical
questions [78]. Simultaneously, it is also necessary to continue to refine
treatment techniques and quality assurance strategies that support the
safe, efficient and effective delivery of SABR to single and multiple
targets [79-81]. 
In summary, at the present time the available data justify the use of
ablative therapies such as SABR for treating selected patients with
early-stage and advanced NSCLC. While the history of surgical
resection for colorectal cancer liver metastases suggests that efforts to
radically change existing treatment paradigms in NSCLC are likely to
encounter scepticism and require time [82], for certain indications, in
particular lung SABR for early stage peripheral NSCLC in medically
inoperable patients, the field may already have moved beyond the need
for randomized controlled trials [83]. While there is a legitimate debate
to be had over the appropriate methodologies and standards of
evidence with which to assess clinical interventions and advanced RT
technologies [22], this should not overshadow the needs of today’s
patients, nor should it deter immediate and pragmatic steps to
responsibly integrate promising treatments and useful technologies into
clinical practice. 
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